Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VERA |
---|---|---|
09:32 ET | 1085 | 40.69 |
09:38 ET | 600 | 40.175 |
09:39 ET | 700 | 40.14 |
09:41 ET | 300 | 39.82 |
09:43 ET | 100 | 39.86 |
09:52 ET | 633 | 39.43 |
09:57 ET | 100 | 39.42 |
10:01 ET | 1500 | 39.35 |
10:03 ET | 864 | 39.275 |
10:06 ET | 300 | 39.51 |
10:12 ET | 100 | 39.52 |
10:14 ET | 381 | 39.285 |
10:15 ET | 1200 | 39.74 |
10:17 ET | 721 | 39.38 |
10:19 ET | 200 | 39.345 |
10:21 ET | 100 | 39.5 |
10:26 ET | 500 | 39.53 |
10:32 ET | 100 | 39.58 |
10:33 ET | 500 | 39.52 |
10:35 ET | 132 | 39.49 |
10:37 ET | 109 | 39.647 |
10:39 ET | 300 | 39.87 |
10:46 ET | 106 | 40.035 |
10:48 ET | 100 | 40.13 |
10:53 ET | 500 | 39.89 |
11:02 ET | 300 | 39.67 |
11:04 ET | 100 | 39.84 |
11:06 ET | 700 | 39.95 |
11:11 ET | 100 | 39.9 |
11:18 ET | 200 | 39.93 |
11:22 ET | 566 | 39.665 |
11:24 ET | 100 | 39.74 |
11:29 ET | 926 | 39.77 |
11:31 ET | 100 | 39.745 |
11:36 ET | 700 | 39.65 |
11:38 ET | 300 | 39.78 |
11:40 ET | 100 | 39.745 |
11:42 ET | 100 | 39.64 |
11:45 ET | 200 | 39.52 |
11:47 ET | 200 | 39.3 |
11:49 ET | 335 | 39.365 |
11:51 ET | 100 | 39.27 |
11:54 ET | 100 | 39.285 |
12:03 ET | 100 | 39.27 |
12:05 ET | 800 | 39.44 |
12:12 ET | 700 | 39.46 |
12:21 ET | 700 | 39.55 |
12:23 ET | 100 | 39.53 |
12:25 ET | 400 | 39.595 |
12:27 ET | 400 | 39.61 |
12:36 ET | 100 | 39.59 |
12:39 ET | 300 | 39.56 |
12:43 ET | 700 | 39.535 |
12:48 ET | 300 | 39.39 |
12:52 ET | 100 | 39.4 |
12:57 ET | 200 | 39.22 |
12:59 ET | 100 | 39.16 |
01:01 ET | 100 | 39.11 |
01:06 ET | 611 | 39.0671 |
01:08 ET | 100 | 39.07 |
01:10 ET | 300 | 39.07 |
01:12 ET | 900 | 39.07 |
01:14 ET | 200 | 39.11 |
01:15 ET | 200 | 39.11 |
01:17 ET | 1200 | 39.11 |
01:19 ET | 100 | 39.25 |
01:21 ET | 100 | 39.29 |
01:24 ET | 100 | 39.21 |
01:28 ET | 800 | 39.19 |
01:33 ET | 600 | 38.88 |
01:35 ET | 851 | 38.925 |
01:37 ET | 100 | 38.94 |
01:39 ET | 270 | 38.97 |
01:44 ET | 100 | 38.99 |
01:50 ET | 2500 | 38.965 |
01:55 ET | 400 | 38.87 |
02:04 ET | 100 | 38.83 |
02:06 ET | 100 | 38.88 |
02:09 ET | 902 | 38.91 |
02:15 ET | 100 | 39.01 |
02:20 ET | 100 | 39 |
02:22 ET | 300 | 39.01 |
02:24 ET | 1200 | 38.95 |
02:26 ET | 400 | 38.895 |
02:27 ET | 200 | 38.885 |
02:33 ET | 603 | 39.12 |
02:40 ET | 200 | 39.22 |
02:44 ET | 354 | 39.2 |
02:45 ET | 100 | 39.21 |
02:47 ET | 400 | 39.22 |
02:49 ET | 100 | 39.27 |
02:51 ET | 700 | 39.13 |
02:54 ET | 100 | 39.06 |
02:56 ET | 500 | 39.12 |
02:58 ET | 300 | 39.08 |
03:02 ET | 417 | 38.98 |
03:03 ET | 400 | 39.06 |
03:05 ET | 200 | 39.04 |
03:09 ET | 200 | 39.04 |
03:12 ET | 100 | 39.02 |
03:14 ET | 1300 | 39.13 |
03:16 ET | 663 | 39.17 |
03:18 ET | 300 | 39.18 |
03:20 ET | 500 | 39.21 |
03:21 ET | 300 | 39.195 |
03:23 ET | 2600 | 39.17 |
03:25 ET | 100 | 39.155 |
03:30 ET | 900 | 39.22 |
03:32 ET | 1300 | 39.255 |
03:34 ET | 1600 | 39.26 |
03:36 ET | 1800 | 39.24 |
03:38 ET | 800 | 39.27 |
03:39 ET | 546 | 39.27 |
03:41 ET | 1000 | 39.21 |
03:43 ET | 200 | 39.26 |
03:45 ET | 2200 | 39.18 |
03:48 ET | 500 | 39.21 |
03:50 ET | 200 | 39.25 |
03:52 ET | 2442 | 39.31 |
03:54 ET | 1204 | 39.22 |
03:56 ET | 12299 | 39.175 |
03:57 ET | 1400 | 39.24 |
03:59 ET | 107561 | 39.12 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vera Therapeutics Inc | 2.2B | -17.8x | --- |
Structure Therapeutics Inc | 2.3B | -16.9x | --- |
Verona Pharma PLC | 2.3B | -17.4x | --- |
Soleno Therapeutics Inc | 2.0B | -20.0x | --- |
Janux Therapeutics Inc | 2.3B | -48.3x | --- |
Edgewise Therapeutics Inc | 2.0B | -12.8x | --- |
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.20 |
Book Value | $2.29 |
P/E Ratio | -17.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.